AU
UK
CA
US
IND
NZ
Last update at 2026-06-12T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
Wed 14 May 25, 08:05 PMZentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
Wed 23 Apr 25, 08:05 PMZentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Wed 26 Mar 25, 08:05 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -221.30000M | -164.55900M | -118.10400M | -46.36300M | -23.42800M |
| Minority interest | -0.30700M | -7.36800M | 24.80M | 6.82M | 7.54M |
| Net income | -220.83100M | -164.26200M | -118.54800M | -46.37800M | -21.06700M |
| Selling general administrative | 54.55M | 40.94M | 33.89M | 8.46M | 4.88M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | 0.01M |
| Reconciled depreciation | 1.43M | 0.54M | 0.16M | 0.11M | 0.05M |
| Ebit | -227.28700M | -216.54200M | -118.78700M | -46.84500M | -23.78300M |
| Ebitda | -233.27400M | -268.52500M | -119.47000M | -46.73400M | -23.73200M |
| Depreciation and amortization | -5.98700M | -51.98300M | -0.68300M | 0.11M | 0.05M |
| Non operating income net other | -16.28200M | 49.75M | - | - | - |
| Operating income | -227.28700M | -216.54200M | -118.78700M | -46.84500M | -23.78300M |
| Other operating expenses | 227.29M | 216.54M | 118.79M | 46.84M | 23.80M |
| Interest expense | 2.58M | 110.05M | 2.23M | 1.20M | 0.00000M |
| Tax provision | -0.46900M | -0.29700M | 0.44M | 0.01M | 0.00400M |
| Interest income | - | - | - | 0.50M | 0.35M |
| Net interest income | - | - | - | 0.50M | 0.35M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.46900M | -0.29700M | 0.44M | 0.01M | 0.00400M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.01M |
| Total operating expenses | 227.29M | 216.54M | 118.79M | 46.84M | 23.80M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 5.99M | 51.98M | 0.68M | 0.48M | 0.35M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -220.83100M | -164.26200M | -118.54800M | -46.37800M | -23.43200M |
| Net income applicable to common shares | -236.80600M | -158.72500M | -117.84100M | -45.66300M | -23.43200M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 562.03M | 539.31M | 454.51M | 365.56M | 102.66M |
| Intangible assets | - | - | - | 8.80M | 8.80M |
| Earning assets | - | - | - | - | - |
| Other current assets | 13.80M | 14.56M | 10.88M | 6.18M | 1.50M |
| Total liab | 124.64M | 105.29M | 90.03M | 32.18M | 19.06M |
| Total stockholder equity | 437.28M | 434.02M | 364.48M | 333.38M | 76.78M |
| Deferred long term liab | - | - | - | - | 0.84M |
| Other current liab | 51.54M | 45.40M | 30.90M | 19.04M | 9.83M |
| Common stock | 0.07M | 0.06M | 0.04M | 0.04M | 0.03M |
| Capital stock | 0.07M | 0.06M | 0.04M | 0.04M | 0.03M |
| Retained earnings | -888.55600M | -596.36500M | -359.55900M | -200.83400M | -82.99300M |
| Other liab | - | 3.47M | 1.62M | 2.48M | 4.16M |
| Good will | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M |
| Other assets | - | 12.35M | 9.67M | 4.30M | 3.22M |
| Cash | 28.04M | 43.07M | 59.71M | 54.95M | 82.42M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 69.37M | 56.65M | 43.94M | 28.60M | 14.90M |
| Current deferred revenue | 0.28M | - | - | - | - |
| Net debt | 17.73M | 2.10M | -13.80200M | -52.95200M | -81.64100M |
| Short term debt | 2.62M | - | 1.45M | 0.90M | 0.78M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 45.77M | 45.17M | 45.91M | 2.00M | 0.78M |
| Other stockholder equity | 1323.58M | 1031.68M | 724.12M | 534.13M | 159.74M |
| Property plant equipment | - | 7.71M | 8.15M | 3.62M | 2.84M |
| Total current assets | 496.72M | 451.93M | 350.77M | 345.10M | 84.07M |
| Long term investments | 0.00000M | 21.21M | 37.49M | - | - |
| Net tangible assets | - | 433.80M | 360.22M | 296.05M | -92.64200M |
| Short term investments | 454.88M | 394.30M | 280.17M | 283.55M | - |
| Net receivables | - | - | 4.44M | 0.42M | 0.14M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | -4.43900M | - | - |
| Accounts payable | 14.93M | 11.25M | 11.59M | 8.66M | 4.29M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 0.22M | 0.53M | 24.80M | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 2.19M | -1.35300M | -0.12500M | 0.04M | -0.16700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.06M | 0.04M | 0.04M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -596.36500M | -359.55900M | -200.83400M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 6.82M | 12.35M | 2.63M | 4.30M | 3.22M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 65.31M | 87.38M | 103.74M | 20.45M | 18.59M |
| Capital lease obligations | 43.15M | 45.17M | 45.91M | 2.00M | 0.78M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -111.63200M | 2.31M | -284.83200M | -0.35200M | -0.22700M |
| Change to liabilities | 15.53M | 13.92M | 14.31M | 7.12M | 0.98M |
| Total cashflows from investing activities | -114.18000M | -18.11500M | -284.83200M | -0.35200M | -0.22700M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 261.04M | 178.52M | 360.44M | 81.83M | 9.47M |
| Change to operating activities | -2.27500M | 2.23M | -6.18600M | -1.39300M | -1.90100M |
| Net income | -237.11300M | -166.09300M | -118.54800M | -46.37800M | -23.43200M |
| Change in cash | -16.88800M | 6.31M | -11.21800M | 42.34M | -15.00600M |
| Begin period cash flow | 62.58M | 56.27M | 67.49M | 25.15M | 40.16M |
| End period cash flow | 45.70M | 62.58M | 56.27M | 67.49M | 25.15M |
| Total cash from operating activities | -163.75100M | -154.09300M | -86.82500M | -39.14300M | -24.25100M |
| Issuance of capital stock | 261.04M | 179.67M | 342.01M | 81.88M | 9.47M |
| Depreciation | 1.43M | 0.54M | 0.16M | 0.11M | 0.05M |
| Other cashflows from investing activities | - | -14.32000M | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 0.88M | -5.51900M | -1.50800M | -1.86100M |
| Change to account receivables | - | 0.41M | -0.27700M | 0.78M | -0.25400M |
| Sale purchase of stock | 261.04M | 179.67M | 346.21M | 81.88M | 9.47M |
| Other cashflows from financing activities | -114.18000M | -1.14600M | 32.65M | 81.83M | 9.46M |
| Change to netincome | 62.41M | 46.38M | 23.01M | -0.09800M | 0.31M |
| Capital expenditures | 2.55M | 6.11M | 0.76M | 0.35M | 0.23M |
| Change receivables | - | 0.41M | -0.27700M | - | - |
| Cash flows other operating | -2.27500M | -50.16400M | -6.18600M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -16.88800M | 6.31M | -11.21800M | - | - |
| Change in working capital | 13.25M | 16.56M | 7.84M | 6.51M | -1.17800M |
| Stock based compensation | 46.84M | 35.74M | 23.15M | 0.62M | 0.31M |
| Other non cash items | 12.61M | -38.37600M | 0.56M | -0.71500M | -2.36500M |
| Free cash flow | -166.29900M | -160.20000M | -87.58300M | -39.49500M | -24.47800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| ZNTL Zentalis Pharmaceuticals Llc |
0.23 6.53% | 3.75 | - | - | - | 2.18 | -2.0265 | |
| NVO Novo Nordisk A/S |
-0.08 0.18% | 43.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.99 4.74% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.115 0.03% | 444.93 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.66 0.11% | 612.14 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
1359 Broadway, New York, NY, United States, 10018
| Name | Title | Year Born |
|---|---|---|
| Dr. Kimberly Lynn Blackwell M.D. | CEO & Director | 1969 |
| Mr. Cameron S. Gallagher M.B.A. | Co-Founder, Pres & Director | 1970 |
| Dr. Kevin D. Bunker Ph.D. | Co-Founder & Chief Scientific Officer | 1972 |
| Ms. Melissa B. Epperly M.B.A. | CFO & Treasurer | 1978 |
| Adam Levy | Sr. VP of Investor Relations | NA |
| Ms. Andrea Paul J.D. | Gen. Counsel & Corp. Sec. | 1981 |
| Dr. Meena Rao Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance | NA |
| Dr. Carrie Brownstein M.D. | Chief Medical Officer | 1970 |
| Dr. Mark Lackner Ph.D. | Chief Translational Officer & Head of Biomarker Strategy | 1967 |
| Dr. Kimberly Lynn Blackwell M.D. | CEO & Director | 1970 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...